Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash from Investing Activities: 2020-2025

Historic Cash from Investing Activities for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to $17.8 million.

  • 4D Molecular Therapeutics' Cash from Investing Activities fell 34.88% to $17.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.9 million, marking a year-over-year increase of 113.58%. This contributed to the annual value of -$302.4 million for FY2024, which is 361.36% down from last year.
  • 4D Molecular Therapeutics' Cash from Investing Activities amounted to $17.8 million in Q3 2025, which was up 228.34% from -$13.9 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Cash from Investing Activities' 5-year high stood at $57.5 million during Q2 2022, with a 5-year trough of -$263.3 million in Q1 2024.
  • Over the past 3 years, 4D Molecular Therapeutics' median Cash from Investing Activities value was $17.8 million (recorded in 2025), while the average stood at -$13.7 million.
  • In the last 5 years, 4D Molecular Therapeutics' Cash from Investing Activities slumped by 39,930.95% in 2021 and then spiked by 7,897.56% in 2022.
  • 4D Molecular Therapeutics' Cash from Investing Activities (Quarterly) stood at -$32.3 million in 2021, then declined by 10.80% to -$35.8 million in 2022, then spiked by 81.32% to -$6.7 million in 2023, then surged by 205.64% to $7.1 million in 2024, then plummeted by 34.88% to $17.8 million in 2025.
  • Its last three reported values are $17.8 million in Q3 2025, -$13.9 million for Q2 2025, and $31.9 million during Q1 2025.